Shawn Cabral
Pfizer (United States)(US)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Pancreatic function and diabetes, Peroxisome Proliferator-Activated Receptors, Asymmetric Hydrogenation and Catalysis
Most-Cited Works
- → Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms(2014)179 cited
- → Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)(2015)81 cited
- → Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing(2020)79 cited
- → Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)(2015)68 cited
- → PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease(2020)41 cited
- → Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family(2016)39 cited
- → New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors(2005)36 cited
- → Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting(2020)29 cited
- → Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis(2022)27 cited
- → Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example(2013)27 cited